This article was originally published in Start Up
Sequella Inc. believes that the technology to meet antibiotic-resistant mycobacterium tuberculosis already exists. The company will acquire intellectual property rights to product opportunities in TB.
You may also be interested in...
Overcoming drug resistance is a key goal of development--but will anyone fund it?
Both providers and users of digital pathology are confident that clinical use cases and the evidence needed to assure payers and encourage investment by commercial labs will overcome challenges around access and adoption.
Pharma companies are applying digital pathology throughout their research and development functions. Where are they now finding value?